Specificity potency

Some Chemical Considerations Relevant to the Mouse Bioassay. Net toxicity, determined by mouse bioassay, has served as a traditional measure of toxin quantity and, despite the development of HPLC and other detection methods for the saxi-toxins, continues to be used. In this assay, as in most others, the molar specific potencies of the various saxitoxins differ, thus, net toxicity of a toxin sample with an undefined mixture of the saxitoxins can provide only a rough approximation of the net molar concentration. Still, to the extent that limits can be placed on variation in toxin composition, the mouse assay can in principle provide useful data on trends in net toxin concentration. However, the somewhat protean chemistry of the saxitoxins makes it difficult to define conditions under which the composition of a mixture of toxins will remain constant thus, attaining a reproducible level of mouse bioassay toxicity is difficult. It is therefore useful to review briefly some of the chemical factors that should be considered when employing the mouse bioassay for the saxitoxins or when interpreting results. Similar concepts will apply to other assays. 

All pharmaceutical finished products undergo rigorous QC testing in order to confirm their conformance to predetermined specifications. Potency testing is of obvious importance, ensuring that the drug will be efficacious when administered to the patient. A prominent aspect of safety testing entails analysis of product for the presence of various potential contaminants. 

Curtin, 2006). In summary, PARP-1 inhibitors have been improved considerably since the development of the benzamide and SAB prototypes, possessing greater specificity, potency, solubility, and pharmokinetics. 

Unless a reference standard label bears a specific potency or content, assume the reference standard is 100.0% pure. 

Calcium antagonists (slow channel blockers, slow Ca2+ antagonists) are a heterogeneous group of substances with widely differing tissue specificities, potency and properties. Some of them exhibit other properties in addition to that of Ca + antagonism. 

How do the conformational and dynamic properties of the peptide hormone or neurotransmitter enter into this process To answer this question we believe several functionally different attributes of the peptide must be considered. As shown in Table 1 these include receptor specificity, potency, efficacy, development of inhibitory properties, and prolongation of biological activities. 

Thus, the use of pharmacological inhibitors of ceramide synthesis or degradation can aid in the elucidation of the mechanisms involved in regulating ceramide levels. Of course, one needs to be cognizant of the shortcomings of a pharmacological approach, including specificity, potency, and mechanisms of action of the employed inhibitors. Complementary molecular approaches (see below) would lend much more support. 

Bios Complex.—In 1901, Ide and his pupil Wildiers showed that a water-soluble factor, termed 6ios, is necessary for the growth and development of many, but not all, strains of the yeast Saccharomyces cerevisice. Bios occurs plentifully in yeast extracts, plant leaves, bran and the outer coats of seeds. In many ways it resembles a vitamin complex, but since it is synthesised by the growing yeast it is now included among the autacoids. Various compounds have been isolated from the mixture of substances present in bios extracts, and their specific potency has been accepted or denied by different workers. 

The second application of the CFTI protocol is the evaluation of the free energy differences between four states of the linear form of the opioid peptide DPDPE in solution. Our primary result is the determination of the free energy differences between the representative stable structures j3c and Pe and the cyclic-like conformer Cyc of linear DPDPE in aqueous solution. These free energy differences, 4.0 kcal/mol between pc and Cyc, and 6.3 kcal/mol between pE and Cyc, reflect the cost of pre-organizing the linear peptide into a conformation conducive for disulfide bond formation. Such a conformational change is a pre-requisite for the chemical reaction of S-S bond formation to proceed. The predicted low population of the cyclic-like structure, which is presumably the biologically active conformer, agrees qualitatively with observed lower potency and different receptor specificity of the linear form relative to the cyclic peptide. 

Although most anesthetics are achiral or are adininistered as racemic mixture, the anesthetic actions are stereoselective. This property can define a specific, rather than a nonspecific, site of action. Stereoselectivity is observed for such barbiturates as thiopental, pentobarbital, and secobarbital. The (3)-enantiomer is modestly more potent (56,57). Additionally, the volatile anesthetic isoflurane also shows stereoselectivity. The (3)-enantiomer is the more active (58). Further evidence that proteins might serve as appropriate targets for general anesthetics come from observations that anesthetics inhibit the activity of the enzyme luciferase. The potencies parallel the anesthetic activities closely (59,60). 

Specific Local Anesthetic Agents. Clinically used local anesthetics and the methods of appHcation are summarized in Table 5. Procaine hydrochloride [51-05-8] (Novocain), introduced in 1905, is a relatively weak anesthetic having along onset and short duration of action. Its primary use is in infiltration anesthesia and differential spinal blocks. The low potency and low systemic toxicity result from rapid hydrolysis. The 4-arninobenzoic acid... 

Saponins. Although the hypocholesterolemic activity of saponins has been known since the 1950s, thek low potency and difficult purification sparked Htde interest in natural saponins as hypolipidemic agents. Synthetic steroids (292, 293) that are structurally related to saponins have been shown to lower plasma cholesterol in a variety of different species (252). Steroid (292) is designated CP-88,818 [99759-19-0]. The hypocholesterolemic agent CP-148,623 [150332-35-7] (293) is not absorbed into the systemic ckculation and does not inhibit enzymes involved in cholesterol synthesis, release, or uptake. Rather, (293) specifically inhibits cholesterol absorption into the intestinal mucosa (253). As of late 1996, CP-148,623 is in clinical trials as an agent that lowers blood concentrations of cholesterol (254). 

Standardization and Testing. RequHements for DTP have been described (17). Standardization of potency for the toxoids reHes on antigenic and flocculation tests. In principle, the antigenic tests are conducted to measure the abUity of the vacciae to Hiduce specific antibodies Hi guHiea pigs. The flocculation test provides a quantitative estimate of the amount of toxoid Hi the vacciae. 

The activity of P-lactamase inhibitors is often expressed as an IC q value, which is defined as the concentration of inhibitor that causes 50% inhibition of en2yme activity for a given set of conditions. IC q values, which vary widely according to substrate, time of incubation, and other factors, are presented herein solely to give an indication of potency and en2yme inhibitor specificity. Values that decrease with preincubation are indicative of irreversible inhibitors. 

The search for new antivkal agents is ongoing and extensive not all vimses have been included here, and new vimses pathogenic to humans will continue to be identified. Novel nucleosides as weU as nonnucleosidic compounds which possess greater potency and enzymic specificity for the future treatment of both acute and persistent human vkal infection will continue to be discovered. 

Edgren carried out a number of studies in which bioassays were used to compare the widely differing potencies of a number of analogues of 17/i-oestradiol that were modified in the 18-position. Commenting on the use of potency ratios, Edgren concluded that they were only valid for specific substances and test systems and useless for product safety testing . These problems could have important consequences for any attempt to establish the potency of specific environmental EDs or environmentally relevant mixtures. 

The form of that function is shown in Figure 3.2. There are two specific parameters that can be immediately observed from this function. The first is that the maximal asymptote of the function is given solely by the magnitude of A/B. The second is that the location parameter of the function (where it lies along the input axis) is given by C/B. It can be seen that when [Input] equals C/B the output necessarily will be 0.5. Therefore, whatever the function the midpoint of the curve will lie on a point at Input = C/B. These ideas are useful since they describe two essential behaviors of any dmg-receptor model namely, the maximal response (A/B) and the potency (concentration of input required for effect C/B). Many of the complex equations... 

---